

New Release of Melatonin Granules "Manlejing®" in China
Japanese Product Name: "Melatobel® Granules for Pediatric Use 0.2%"

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Jin Shiomura) is pleased to announce that as of January 13, 2026, melatonin granules "Manlejing®," a product with Japanese name of "Melatobel® Granules for Pediatric Use 0.2%" ("the product") was launched in China.

In China, there had been no approved or marketed prescription medicines for "sleep-onset difficulty associated with neurodevelopmental disorders in children." For that reason, the company began the development of this product and obtained its approval. Nobelpharma has entered into a sales consignment agreement with Beijing Dainkang Health Pharmaceutical Co., Ltd.* (Headquarters: Beijing, China; CEO: Jie Yang, hereinafter "Dain") for this product, and the sales of which will be conducted through Dain.

We hope the launch of this product will contribute to improving sleep-onset in children with neurodevelopmental disorders in China.

Nobelpharma is determined to continue contribution to society by providing critical but neglected pharmaceuticals and medical devices.

*Beijing Dainkang Health Pharmaceutical Co., Ltd.

Founded in China in 1994. The company operates with the philosophy of realizing health and well-being for pediatric patients in China, developing and marketing pediatric drugs and health food including ADHD medications, prescription and OTC drugs such as antipyretic analgesics, and health supplements.

[Contact Information]

<https://www.nobelpharma.co.jp/en/contact/general-form>

Etsuro Hayashi, Head of Communications

17-24, Shinkawa 1-chome, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800